Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab.

ABSTRACT:

Purpose

Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective.

Methods

In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index ≥ 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn's disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12.

Results

Twen

SUBMITTER: Husman J 

PROVIDER: S-EPMC11422436 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature